Brief: Atara Biotherapeutics Inc - On March 31, Entered Amendment To Commercialization Agreement With Pierre Fabre - SEC Filing
04/04/2025 23:05
April 4 (Reuters) - Atara Biotherapeutics Inc ATRA.O: ATARA BIOTHERAPEUTICS INC - ON MARCH 31, ENTERED AMENDMENT TO COMMERCIALIZATION AGREEMENT WITH PIERRE FABRE - SEC FILING ATARA BIOTHERAPEUTICS INC - BIO TO RECEIVE UP TO $550 MILLION IN MILESTONE PAYMENTS - SEC FILING ATARA BIOTHERAPEUTICS INC - PIERRE FABRE TO ASSUME COSTS FOR FDA REMEDIATION TO SUPPORT BLA RESUBMISSION FOR TAB-CEL - SEC FILING Source text: [ID:n0000950170-25-051121] Further company coverage: ATRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atara Biotherapeutics
See all newsAtara Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atara Biotherapeutics Q2 revenue falls on deferred revenue recognition
Brief: Atara Biotherapeutics Q2 EPS USD -0.32
Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a share - Earnings Preview
Brief: Atara Biotherapeutics - May Offer Up To $79.27 Million In Common Stock As Of May 12, 2026 - SEC Filing